PHOTOKINETIC OCULAR DRUG DELIVERY METHODS AND APPARATUS
First Claim
6-1. The method of claim 4, wherein the biologically active substance is insulin.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates generally to transscleral, transcorneal, and transocular delivery of biologically active substances through the tissues, blood vessels and cellular membranes of the eyes of patients without causing damage to the cellular surface, tissue or membrane. The invention provides compositions and methods for enhanced transscleral, transcorneal and transocular delivery of biologically active substances using pulsed incoherent light, and particularly the transcleral, transcorneal or transocular delivery of high molecular weight biologically active substances to a patient using pulsed incoherent light. The invention further provides a device for the application of the pulsed incoherent light to cellular surfaces and membranes of the eye of a subject using those compositions and methods.
-
Citations
47 Claims
-
6-1. The method of claim 4, wherein the biologically active substance is insulin.
-
21-2. The method according to claim 24 wherein the fluorescent light has a wavelength range from about 260 nm to about 760 nm.
-
22-3. The method according to claim 24 wherein the ultraviolet light has a wavelength range from about 340 nm to about 900 mm.
-
23-4. The method according to claim 24 wherein the visible light has a wavelength range from about 340 nm to about 900 nm.
-
24-5. The method according to claim 24 wherein the near infrared light has a wavelength range from about 340 nm to about 900 nm.
-
30. A device for photokinetic transscleral ocular drug delivery, the device comprising:
-
a generator that provides an oscillating electrical pulse; at least one light emitting diode that receives the oscillating electrical pulse and responds by providing an incoherent light; and a drug reservoir cell that holds a solution comprising a high molecular weight biologically active substance and a solvent;
wherein;the drug reservoir cell is positioned to receive the incoherent light. - View Dependent Claims (31, 32, 33, 34, 35, 36)
-
-
37. An in-vitro method of photokinetic transscleral drug delivery to the eye of a subject, the method comprising:
-
preparing a solution comprising a biologically active substance and a solvent; applying the solution to an ocular cellular surface of a subject; illuminating the solution on the ocular cellular surface with a pulsed incoherent light having a selected wavelength, pulse rate and pulse duration with a device; and allowing the solution to permeate through the ocular cellular surface.
-
-
38. A method for the transcleral delivery of one or more high molecular weight biologically active substances to the eye of a subject, the method comprising:
-
preparing a solution comprising a high molecular weight biologically active substance and a solvent; applying the solution to an ocular cellular surface of a subject; illuminating the solution on the ocular cellular surface with a pulsed incoherent light having a selected wavelength, pulse rate and pulse duration with a device; and allowing the solution to permeate through the ocular cellular surface. - View Dependent Claims (39, 40, 41, 42, 43, 44)
-
Specification